Tradjenta in Phase III trial for Diabetic Nephropathy
Boehringer Ingelheim and Eli Lilly and Company have initiated a study of the efficacy and safety of Tradjenta ( linagliptin) in patients with Type 2 Diabetes with prevalent albuminuria (defined as urinary albumin-to-creatinine ratio (UACR) 30-3000 mg/g creatinine), while remaining on current standard therapy for Diabetic Nephropathy.
The name of the clinical trial is MARLINA (efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin), and it can be found on ClinicalTrials.gov under identifier number, NCT01792518.
The primary endpoint of MARLINA is the change from baseline in HbA1c after 24 weeks of treatment. The study is expected to be completed in 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.